Diphenhydramine

Generic Name: Diphenhydramine

Brand Names: Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₁NO

CAS Number: 58-73-1

Unique Ingredient Identifier: 8GTS82S83M

Background: Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both ...

Indication: Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insom...

Associated Conditions: Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes

Associated Therapies: Airway secretion clearance therapy, Expectorant

Clinical Trials

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Montelukast
Drug: Daratumumab
Biological: Autologous Stem Cell Transplant (ASCT)

First Posted Date: 2020-02-13

Last Posted Date: 2024-06-14

Lead Sponsor: University of Miami

Target Recruit Count: 306

Registration Number: NCT04268498

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

Phase 3

Completed

Conditions: Lung Cancer
Ovarian Cancer
Breast Cancer
Oesophageal Cancer
Head Cancer Neck
Cervical Cancer
Endometrial Cancer

Interventions: Drug: Cetirizine
Drug: Diphenhydramine
Drug: Lactose pill
Drug: Sodium chloride 0.9%

First Posted Date: 2020-01-22

Last Posted Date: 2020-10-12

Lead Sponsor: Ciusss de L'Est de l'Île de Montréal

Target Recruit Count: 27

Registration Number: NCT04237090

Locations: 🇨🇦
CIUSSS de l'Est-de-l'île-de-Montréal, Montréal, Quebec, Canada

Stem Cell Transplantation in Crohn's Disease

Phase 1

Recruiting

Conditions: Crohn Disease

Interventions: Drug: Mesna
Drug: Cyclophosphamide
Drug: Filgrastim
Procedure: Apheresis catheter placement
Procedure: Leukapheresis
Drug: Fludarabine
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: anti-thymocyte globulin (rabbit)
Drug: lymphocyte immune globulin
Biological: Peripheral Blood Stem Cell Infusion
Drug: Cytoxan

First Posted Date: 2020-01-13

Last Posted Date: 2024-04-10

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 15

Registration Number: NCT04224558

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

Phase 3

Active, not recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Obinutuzumab
Drug: MMF
Drug: Prednisone
Drug: Placebo
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2020-01-09

Last Posted Date: 2024-10-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 271

Registration Number: NCT04221477

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇩🇪
Universitaetsmedizin Johannes Gutenberg; Rheumatologie, Mainz, Germany

and more 78 locations

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Phase 3

Completed

Conditions: Multiple Sclerosis
Infusion Reaction

Interventions: Drug: cetrizine
Drug: diphenhydramine

First Posted Date: 2019-11-25

Last Posted Date: 2024-03-04

Lead Sponsor: Providence Health & Services

Target Recruit Count: 19

Registration Number: NCT04175834

Locations: 🇺🇸
Providence Neurological Specialties West, Portland, Oregon, United States

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Pembrolizumab
Biological: Boserolimab
Biological: MK-4830
Biological: MK-0482
Drug: diphenhydramine
Drug: acetaminophen

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 135

Registration Number: NCT04165096

Locations: 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸
Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
🇺🇸
City of Hope ( Site 0014), Duarte, California, United States

and more 36 locations

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Inotuzumab ozogamicin
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Methylprednisolone

First Posted Date: 2019-04-12

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT03913559

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States